Compare RYOJ & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYOJ | ELTX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 63.3M |
| IPO Year | 2024 | 2014 |
| Metric | RYOJ | ELTX |
|---|---|---|
| Price | $2.74 | $1.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 11.0K | ★ 304.4K |
| Earning Date | 03-23-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $1.71 |
| 52 Week High | $11.43 | $16.00 |
| Indicator | RYOJ | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 27.54 |
| Support Level | $2.84 | $1.74 |
| Resistance Level | $2.95 | $3.32 |
| Average True Range (ATR) | 0.31 | 0.11 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 15.72 | 21.43 |
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.